PBAC's latest decision on Abiraterone: Recommended with restriction (2012). Considered for for the treatment of metastatic advanced prostate cancer (castration resistant prostate cancer) in patients who have received prior chemotherapy containing a taxane.
PBAC outcome
Recommended with restriction
Authority Required
ICER (AUD/QALY)
$75k/QALY
$45k/QALY–$75k/QALY · across 4 submissions
Submissions
4
first 2011
PBS spend
$53M
15,666 scripts · 2024
Eligible population
patients with metastatic castrate resistant prostate cancer who have progressing disease after treatment with docetaxel
Therapy area
Oncology
Line of therapy
Later-line
Evidence base
Cost-minimisation
Comparator
50% best supportive care and 50% cabazitaxel
Economic model
CUA | CEA
ICER basis
Range aggregates 4 submissions (2011–2012) — not a single base case.
Risk sharing
Risk-sharing arrangement in place — a risk share agreement would be required to mitigate the financial risk to Government of treatment beyond progression and use in patients who had not previously been treated with docetaxel.
PBS expenditure
The Australian government paid $53M in PBS benefits for Abiraterone in 2024 across 15,666 scripts, at $3,390 per script.
Submission history
Nov 2011: Not recommended — ICER $200k/QALY
Mar 2012: Not recommended — ICER $200k/QALY
Jul 2012: Not recommended — ICER $200k/QALY
Nov 2012: Recommended with restriction · Authority Required — ICER $75k/QALY